Phosphatidylazidothymidine and phosphatidyl-ddC: assessment of uptake in mouse lymphoid tissues and antiviral activities in human immunodeficiency virus-infected cells and in Rauscher leukemia virus-infected mice.
During the early stages of human immunodeficiency virus (HIV) infection, although symptoms are absent and viral replication in peripheral blood mononuclear cells is low, substantial levels of HIV replication can be documented in lymphoid tissue [G. Pantaleo, C. Graziosi, J.F. Demarest, L. Butini, M. Montroni, C.H. Fox, J.M. Orenstein, D.P. Kotler, and A.S. Fauci, Nature (London) 362:355-358, 1993, and J. Embretsen, M. Zupancic, J.L. Ribas, A. Burke, P. Racz, K. Tenner-Tacz, and A.T. Haase, Nature (London) 362:359-362, 1993]. This observation suggests that earlier treatment of HIV infection may be indicated and that strategies for enhancing drug targeting to the lymphoid tissue reservoris of HIV infection may be beneficial. To address this issue, we synthesized dioleoylphosphatidyl-ddC (DOP-ddC) and dipalmitoylphosphatidyl-3'-azido-3'-deoxythymidine (DPP-AZT), phospholipid prodrugs which form lipid bilayers and which are readily incorporated into liposomes. The anti-HIV activity of DOP-ddC was similar to that of ddC in HIV type 1-infected HT4-6C cells, but DPP-AZT was considerably less active than AZT in HT4-6C cells. Liposomes containing DOP-[3H]ddC or DPP-[3H]AZT administered intraperitoneally to mice produced greater levels of total radioactivity over time in plasma, spleen, and lymphoid tissue relative to the results with [3H]ddC and [3H]AZT, respectively. DPP-AZT administered intraperitoneally in liposomes as a single daily dose to mice infected with Rauscher leukemia virus prevented increased spleen weight and reverse transcriptase levels in serum with a dose-response roughly comparable to that of AZT given continuously in the drinking water. DOP-ddC, DPP-AZT, and lipid conjugates of other antiretroviral nucleosides may provide higher levels of drug over time in plasma and in lymph nodes and spleen, important reservoirs of HIV infection, and may represent an interesting alternative approach to antiviral nucleoside treatment of AIDS.
Hostetler
K Y
KY
Department of Medicine, University of California, San Diego, La Jolla 92093-0676, USA.
Richman
D D
DD
Sridhar
C N
CN
Felgner
P L
PL
Felgner
J
J
Ricci
J
J
Gardner
M F
MF
Selleseth
D W
DW
Ellis
M N
MN
D000818:Animals; D005260:Female; D006678:HIV / Q000187:drug effects*; D008221:Lymphoid Tissue / Q000378:metabolism*; D051379:Mice; D008807:Mice, Inbred BALB C; D010743:Phospholipids / Q000493:pharmacokinetics* / Q000494:pharmacology; D011355:Prodrugs / Q000493:pharmacokinetics* / Q000494:pharmacology; D011925:Rauscher Virus / Q000187:drug effects*; D016047:Zalcitabine / Q000493:pharmacokinetics* / Q000494:pharmacology; D015215:Zidovudine / Q000493:pharmacokinetics* / Q000494:pharmacology
D010743:Phospholipids; D011355:Prodrugs; D015215:Zidovudine; D016047:Zalcitabine